🔎 Trials Near Me

Gara Jalqabaatti › Dhukkuba Kroonii › Illinois

Qorannoo klinikaalii Dhukkuba Kroonii Illinois keessatti

Qorannoo 18 Dhukkuba Kroonii f Illinois keessatti hirmaatuu jiru.

Magaalota Illinois keessatti

Takkalaa qorannoo (Ingiliffa)

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

  • Midwest Digestive Health & Nutrition /ID# 285250, Des Plaines
  • Gi Alliance - Glenview /ID# 283932, Glenview
  • Illinois Gastroenterology Group /ID# 283933, Gurnee
  • fi 1 dabalataa
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT07697456

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  • University of Chicago Medical Center ( Site 5066), Chicago
  • Endeavor Health ( Site 5018), Evanston
  • GI ALLIANCE - GURNEE ( Site 5003), Gurnee
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 16 hanga 80 · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT06430801

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

  • Yapp, Rockford M.D. (Private Practice), Downers Grove
  • GI Alliance - Glenview, Glenview
  • Gastroenterology and Internal Medicine Specialists, SC, Lake Barrington
  • fi 3 dabalataa
Namoota walitti qabaa jiraSadarkaa 4
Umuriin 18 hanga 80 · Saalaa hunda · Haaromfame 30-Ful-2026 · NCT06581328

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  • University of Chicago Medical Center /ID# 267400, Chicago
  • OSF St. Francis Medical Center /ID# 266973, Peoria
  • Springfield Clinic Main Campus /ID# 267434, Springfield
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06548542

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  • Rush University Medical Center, Chicago
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 hanga 70 · Saalaa hunda · Haaromfame 24-Ful-2026 · NCT06937099

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • Rush University Medical Center-Site Number: 8400015, Chicago
  • Midwest Digestive Health and Nutrition-Site Number: 8400136, Des Plaines
  • GI Alliance - Glenview-Site Number: 8400068, Glenview
  • fi 1 dabalataa
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 16 hanga 80 · Saalaa hunda · Haaromfame 23-Ful-2026 · NCT07184931

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • Illinois Gastroenterology Group d/b/a GI Alliance - Gurnee-Site Number: 8400049, Gurnee
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 16 hanga 80 · Saalaa hunda · Haaromfame 23-Ful-2026 · NCT07184944

A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

  • Rush University Medical Center, Chicago
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 80 · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07483099

A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

  • Rush University Medical Center, Chicago
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 80 · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07483073

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

  • University of Chicago Medicine, Chicago
Namoota walitti qabaa jiraSadarkaa 4
Umuriin 18 hanga 70 · Saalaa hunda · Haaromfame 09-Ful-2026 · NCT06045754

Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

  • University of Chicago Medicine, Chicago
Namoota walitti qabaa jira
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 07-Hag-2026 · NCT05230173

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

  • OSF St. Francis Medical Center /ID# 262192, Peoria
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 2 hanga 17 · Saalaa hunda · Haaromfame 24-Wax-2026 · NCT06332534

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  • Advocate Children's Hospital Park Ridge, Park Ridge
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 2 hanga 17 · Saalaa hunda · Haaromfame 22-Wax-2026 · NCT06405087

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  • Advocate Children's Hospital - Park Ridge - PIN, Park Ridge
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 2 fi ol · Saalaa hunda · Haaromfame 07-Cam-2026 · NCT05442567

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

  • Advocate Children's Hospital Park Ridge, Park Ridge
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 2 hanga 17 · Saalaa hunda · Haaromfame 05-Cam-2026 · NCT04779320

Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

  • Northwestern University, Evanston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 27-Elb-2026 · NCT06456593

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

  • Mirador Therapeutics Selected Site, Glenview
  • Mirador Therapeutics Selected Site, Gurnee
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 80 · Saalaa hunda · Haaromfame 12-Bit-2026 · NCT07113522

Treatment of Moderate to Severe Refractory Crohn's Disease

  • Northwestern, Chicago
  • University of Chicago, Chicago
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 hanga 65 · Saalaa hunda · Haaromfame 10-Mud-2025 · NCT06721962

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.